Salarius Pharma falls as FDA puts cancer drug trial on partial clinical hold
11/07/2024 13:52
** Shares of drug developer Salarius Pharmaceuticals
SLRX.O fall 20.8% to $2.17 premarket
** Co says FDA has placed a partial clinical hold on its
early-stage trial studying its experimental drug seclidemstat in
combination with chemotherapy drug azacitidine in adult patients
with type of blood cancer
** No new patients may be enrolled at this time; currently
enrolled patients may continue treatment and all study
procedures if they are benefiting
** On July 9, researchers at The University of Texas MD
Anderson Cancer Center (MDACC) notified co that a patient
experienced unexpected serious adverse event - filing
** Co intends to support researchers at MDACC to analyze the
available data and respond to questions submitted by the FDA
** Up to last close, stock down 47.26% YTD
(Reporting by Sriparna Roy in Bengaluru)
((Sriparna.Roy@thomsonreuters.com;))